Ultrasensitive monitoring of HIV-1 viral load by a low-cost real-time reverse transcription-PCR assay with internal control for the 5' long terminal repeat domain
dc.contributor.author | Drosten, Christian | |
dc.contributor.author | Panning, Marcus | |
dc.contributor.author | Drexler, Jan Felix | en_ZA |
dc.contributor.author | Hänsel, Florian | |
dc.contributor.author | Pedroso, Celia | |
dc.contributor.author | Yeats, Jane | |
dc.contributor.author | Samuel, Matthew | |
dc.contributor.author | Liedigk, Britta | |
dc.contributor.author | Lippert, Ute | |
dc.contributor.author | Stürmer, Martin | |
dc.contributor.author | Doerr, Hans Wilhelm | |
dc.contributor.author | Brites, Carlos | |
dc.contributor.author | Preiser, Wolfgang | |
dc.contributor.author | De Souza Luna, Luciano Kleber | |
dc.date.accessioned | 2010-11-03T06:17:57Z | |
dc.date.available | 2010-11-03T06:17:57Z | |
dc.date.issued | 2006-04 | |
dc.description | Bibliography | |
dc.description.abstract | BACKGROUND: Current HIV-1 viral-load assays are too expensive for resource-limited settings. In some countries, monitoring of antiretroviral therapy is now more expensive than treatment itself. In addition, some commercial assays have shown shortcomings in quantifying rare genotypes. METHODS: We evaluated real-time reverse transcription-PCR with internal control targeting the conserved long terminal repeat (LTR) domain of HIV-1 on reference panels and patient samples from Brazil (n = 1186), South Africa (n = 130), India (n = 44), and Germany (n = 127). RESULTS: The detection limit was 31.9 IU of HIV-1 RNA/mL of plasma (> 95% probability of detection, Probit analysis). The internal control showed inhibition in 3.7% of samples (95% confidence interval, 2.32%-5.9%; n = 454; 40 different runs). Comparative qualitative testing yielded the following: Roche Amplicor vs LTR assay (n = 431 samples), 51.7% vs 65% positives; Amplicor Ultrasensitive vs LTR (n = 133), 81.2% vs 82.7%; BioMerieux NucliSens HIV-1 QT (n = 453), 60.5% vs 65.1%; Bayer Versant 3.0 (n = 433), 57.7% vs 55.4%; total (n = 1450), 59.0% vs 63.8% positives. Intra-/interassay variability at medium and near-negative concentrations was 18%-51%. The quantification range was 50-10,000,000 IU/mL. Viral loads for subtypes A-D, F-J, AE, and AG yielded mean differences of 0.31 log(10) compared with Amplicor in the 10(3)-10(4) IU/mL range. HIV-1 N and O were not detected by Amplicor, but yielded up to 180 180.00 IU/mL in the LTR assay. Viral loads in stored samples from all countries, compared with Amplicor, NucliSens, or Versant, yielded regression line slopes (SD) of 0.9 (0.13) (P < 0.001 for all). CONCLUSIONS: This method offers all features of commercial assays and covers all relevant genotypes. It could allow general monitoring of antiretroviral therapy in resource-limited settings. | en_ZA |
dc.format.extent | 8 p. : ill. | |
dc.identifier.citation | Drosten, C, Panning, M, Drexler, JF, Hansel, F, Pedroso, C, Yeats, J, De Souza Luna, LK, Samuel, M, Liedigk, B, Lippert, U, Sturmer, M, Doerr, HW, Brites, C & Preiser, W 2006, 'Ultrasensitive monitoring of HIV-1 viral load by a low-cost real-time reverse transcription-PCR assay with internal control for the 5' long terminal repeat domain', Clinical Chemistry, vol. 52, pp. 1258-1266, DOI: 10.1373/clinchem.2006.066498 | en_ZA |
dc.identifier.issn | 0009-9147 (print) | |
dc.identifier.issn | 1530-8561 (online) | |
dc.identifier.other | 10.1373/clinchem.2006.066498 | |
dc.identifier.uri | http://hdl.handle.net/10019.1/4857 | |
dc.language.iso | en_ZA | en_ZA |
dc.publisher | American Association for Clinical Chemistry | en_ZA |
dc.rights.holder | American Association for Clinical Chemistry | en_ZA |
dc.subject | Brazil | en_ZA |
dc.subject | Genotype | en_ZA |
dc.subject | Germany | en_ZA |
dc.subject | HIV infections drug therapy | en_ZA |
dc.subject | HIV infections virology | en_ZA |
dc.subject | HIV Long Terminal Repeat | en_ZA |
dc.subject | HIV-1* genetics | en_ZA |
dc.subject | India | en_ZA |
dc.subject | RNA | en_ZA |
dc.subject | Viral analysis | en_ZA |
dc.subject | Regression analysis | en_ZA |
dc.subject | Reverse Transcriptase Polymerase Chain Reaction economics | en_ZA |
dc.subject | South Africa | en_ZA |
dc.subject | Viral Load | en_ZA |
dc.subject | RNA | en_ZA |
dc.subject.lcsh | Highly active retroviral therapy -- South Africa -- Testing | en_ZA |
dc.subject.lcsh | Viral diseases therapy -- Testing -- Economic aspects -- India | en_ZA |
dc.subject.lcsh | Viral diseases therapy -- Testing -- Economic aspects -- Brazil | en_ZA |
dc.subject.lcsh | Viral diseases therapy -- Testing -- Economic aspects -- Germany | en_ZA |
dc.title | Ultrasensitive monitoring of HIV-1 viral load by a low-cost real-time reverse transcription-PCR assay with internal control for the 5' long terminal repeat domain | en_ZA |
dc.type | Article | en_ZA |